Steady-state pharmacokinetics of metformin is independent of the OCT1 genotype in healthy volunteers

Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin

(2014) S Goswami et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

(2014) Anila K. Madiraju et al.   NATURE

Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis

(2014) Kaixin Zhou et al.   Lancet Diabetes & Endocrinology

A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin

(2013) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

(2012) S L Stocker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population

(2012) Rasmus Steen Pedersen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients

(2012) Linda Tarasova et al.   Pharmacogenetics and Genomics

Clinical Pharmacokinetics of Metformin

(2011) Garry G. Graham et al.   CLINICAL PHARMACOKINETICS

A Common 5′-UTR Variant in MATE2-K Is Associated With Poor Response to Metformin

(2011) J H Choi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status

(2011) X. Stephenne et al.   DIABETOLOGIA

The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c

(2011) Mette M.H. Christensen et al.   Pharmacogenetics and Genomics

OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine

(2010) Zhi-Jun Wang et al.   Pharmacogenetics and Genomics

The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin

(2009) M V Tzvetkov et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver

(2009) Anne T. Nies et al.   HEPATOLOGY

Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin

(2009) Ying Chen et al.   Pharmacogenetics and Genomics

Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response

(2009) Matthijs L. Becker et al.   Pharmacogenetics and Genomics

Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus

(2009) M L Becker et al.   PHARMACOGENOMICS JOURNAL

Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin

(2008) IS Song et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS